Theravance Biopharma Inc [TBPH] stock is trading at $13.91, up 1.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The TBPH shares have gain 5.78% over the last week, with a monthly amount glided 24.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on August 06, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $10 from $15. Previously, BTIG Research started tracking the stock with Buy rating on April 12, 2024, and set its price target to $21. On January 08, 2024, downgrade downgraded it’s rating to In-line. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $12 on May 23, 2022. JP Morgan upgraded its rating to a Neutral but $12 remained the price target by the analyst firm on November 05, 2021. JP Morgan downgraded its rating to Underweight for this stock on September 15, 2021, but kept the price target unchanged to $7. In a note dated August 25, 2021, Morgan Stanley downgraded an Underweight rating on this stock and revised its target price from $27 to $14.
Theravance Biopharma Inc [TBPH] stock has fluctuated between $7.88 and $14.30 over the past year. Currently, Wall Street analysts expect the stock to reach $15.33 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $13.91 at the most recent close of the market. An investor can expect a potential return of 10.21% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
Theravance Biopharma Inc [NASDAQ:TBPH] reported sales of 77.20M for the trailing twelve months, which represents a growth of 83.75%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -0.48%, Pretax Profit Margin comes in at 0.52%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.07 and Total Capital is -0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.73 points at the first support level, and at 13.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.01, and for the 2nd resistance point, it is at 14.10.
Ratios To Look Out For
For context, Theravance Biopharma Inc’s Current Ratio is 6.70. On the other hand, the Quick Ratio is 6.70, and the Cash Ratio is 5.16. Considering the valuation of this stock, the price to sales ratio is 9.07, the price to book ratio is 3.12 and price to earnings (TTM) ratio is 59.47.
Transactions by insiders
Recent insider trading involved Farnum Rhonda, SVP, COMM & MEDICAL AFFAIRS, that happened on Jul 14 ’25 when 10000.0 shares were sold. Officer, RHONDA FARNUM completed a deal on Jul 14 ’25 to buy 10000.0 shares. Meanwhile, SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold 24000.0 shares on Jun 02 ’25.
